May 22, 2014 - ZOLL LifeVest Wearable Defibrillator to be Showcased at SCAI 2014

 

MEDIA CONTACT:  

Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637
degan@zoll.com
 

ZOLL LIFEVEST WEARABLE DEFIBRILLATOR TO BE SHOWCASED AT SCAI 2014


May 22, 2014—CHELMSFORD, MASS.—ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it will highlight the LifeVest® Wearable Defibrillator, along with sudden cardiac death (SCD) education and screening tools, in Booth #400 at the 2014 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions, May 28-31 at Caesars Palace in Las Vegas.

The LifeVest will be discussed during the C3 Summit for Interventional Cardiology Fellows at SCAI 2014:

  • J. Jeffrey Marshall, MD, FSCAI, FACC, Northeast Georgia Heart Center, will present, “You Got Them Through the PCI. Now What?” on Friday, May 30, at 12:00 p.m. at Caesars Palace, Neapolitan II.*

The LifeVest protects patients at risk for SCD. It is used for a wide range of patient conditions or situations, including following a recent myocardial infarction or coronary revascularization. One in five post-acute myocardial infarction (AMI) patients have been shown to be at high risk of dying after percutaneous coronary intervention (PCI).1 The majority of mortality in AMI patients post-PCI occurs in the first three months—one out of every 10 high-risk patients die, with about 60% of this mortality due to SCD.1,2 The LifeVest gives physicians time to optimize medical therapy and assess a patient’s long-term risk for sudden death.

The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCD. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.

The LifeVest is covered by most health plans in the United States, including commercial, state, and federal plans.

About ZOLL Medical Corporation

ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care. For more information, visit www.zoll.com. 

About Asahi Kasei

ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care. For more information, visit www.asahi-kasei.co.jp/asahi/en/.

*This event is not part of the official SCAI Annual Scientific Sessions as planned by the SCAI Program Committee.

Copyright © 2014 ZOLL Medical Corporation. All rights reserved. LifeVest and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All trademarks are the property of their respective owners.

1Halkin, A et al. Prediction of Mortality After Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: CADILLAC Risk Score. JACC 2005;45:1397–1405.

2Stone, G et al. Prevention of Sudden Cardiac Arrest Post PTCA in High-Risk Patients. http://www.theheart.org/article/1202823.do (April 2011).